Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study

Sung Han Kim, Jae Young Joung, Sohee Kim, Koon Ho Rha, Hyeong Gon Kim, Cheol Kwak, Ji Youl Lee, Seong Soo Jeon, Sung Kyu Hong, Hyeon Jeong, Moon Ki Jo, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Choung Soo Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The multi-centre, prospective, observational study was designed to examine the efficacy of continuous combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density (BMD) change during 12 months post-androgen deprivation therapy (ADT) in Asian prostate cancer patients. Multiple regression analysis and estimated the 10-year probability of major fractures among the patients with Fracture Risk Assessment Tool were conducted to investigate the underlying factors affecting BMD. Paired t-test to evaluate the change of BMD from baseline to 12 month, and two sample t-test to examine the difference of BMD changes were used between two groups. BMD significantly decreased in both the CAB and GnRH groups, with no group wise differences. The proportion of osteopenia or osteoporosis was slightly increased after the 12-month post-ADT. Ten-year probability of hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively. In conclusion, a significant decrease of BMD by 12-month ADT was observed without any differences between the two groups, whereas ADT-related BMD loss did not induce detrimental effects on bone health in terms of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of fracture during ADT in an Asian population.

Original languageEnglish
Article number39562
JournalScientific reports
Volume7
DOIs
Publication statusPublished - 2017 Mar 6

All Science Journal Classification (ASJC) codes

  • General

Fingerprint Dive into the research topics of 'Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study'. Together they form a unique fingerprint.

Cite this